Sihuan Pharmaceutical Holdings Group Ltd. (SIHUAN PHARM) disclosed that it bought back 10.00 million ordinary shares on 27 August 2026 through on-exchange transactions.

• Transaction details: The shares were repurchased within a price range of HK$0.77–0.82, at a volume-weighted average cost of HK$0.8111 per share, for a total cash outlay of HK$8.11 million.

• Capital structure impact: Outstanding shares (excluding treasury stock) fell by 0.11% to 9.12 billion, while treasury shares increased from 204.01 million to 214.01 million. Total issued shares remained unchanged at 9.33 billion, as the repurchased shares are being held in treasury rather than cancelled.

• Utilisation of mandate: The repurchase represents 0.11% of the 912.60 million shares authorised for buyback under the mandate approved on 26 June 2026, leaving approximately 902.60 million shares available.

• Moratorium: In accordance with Hong Kong listing rules, the company cannot issue new shares or dispose of treasury shares until 26 September 2026, 30 days after the transaction date.

The company confirmed that the repurchase complied with the Hong Kong Stock Exchange’s Main Board Rules and that no material changes have been made to the previously filed explanatory statement.